Imricor — Q3 CY2026 Earnings Summary

Imricor Medical Systems commenced its U.S. commercial launch in the third quarter of 2026, securing its first two hospital customers, Rady Children's Hospital–San Diego and Children's Medical Center Dallas, for its NorthStar interventional MR system. The company reported revenue of US$188k, a 437% increase from the prior period, driven by initial sales and installations while maintaining a cash balance of US$62.1m. Regulatory progress included FDA 510(k) clearances for pediatric label expansions on NorthStar and the Vision-MR Diagnostic Catheter, as well as the acceptance of the manufacturing module for the Vision-MR Ablation Catheter PMA application. Additionally, Imricor established a strategic partnership with Philips to issue a Third Party Product Compatibility Declaration, enabling NorthStar to operate on the Philips MR installed base and launching a joint turnkey iMR lab solution.